Delivery Order SPE2DB20D3303-SPE2DB25FA2PX

AmerisourceBergen Drug Corp was awarded a delivery order valued at $1,701.73 by the Defense Logistics Agency (DLA) on August 14, 2025, for the supply of Konvomep 2-84 mg/mL oral suspension in a 300mL volume. This is a firm fixed price delivery order with no set-aside designation, indicating it was awarded through competitive procurement. The contract is to be performed at the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026.

As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen utilizes the SPE2DX IDC as a comprehensive global pharmaceutical support vehicle to supply military healthcare systems worldwide. The parent IDC encompasses a broad portfolio of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The DLA awarded this delivery order as part of its ongoing medical supply chain operations supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The DLA Troop Support is planning to establish the Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, demonstrating continued reliance on qualified distributors like AmerisourceBergen to meet military healthcare pharmaceutical requirements.